A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

Yui Takeshige, Yoshihide Fujisawa, Asadur Rahman, Wararat Kittikulsuth, Daisuke Nakano, Hirohito Mori, Tsutomu Masaki, Koji Ohmori, Masakazu Kohno, Hiroaki Ogata, Akira Nishiyama
  • Hypertension Research, January 2016, Springer Science + Business Media
  • DOI: 10.1038/hr.2016.2

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1038/hr.2016.2

The following have contributed to this page: Professor Hiroaki Ogata

In partnership with: